Table 3 |
||||
|
Autoantibodies as prognostic markers of poor outcomes |
||||
|
Autoantibody |
Measure |
Outcomes at 30 months |
||
|
|
||||
|
Persistence |
RA criteria |
Severity |
||
|
|
||||
|
RF |
Sensitivity |
47.2 |
57.1 |
55.4 |
|
Specificity |
91.7 |
62.8 |
63.0 |
|
|
Positive LR |
5.69 |
1.53 |
1.50 |
|
|
Anti-Sa |
Sensitivity |
34.4 |
39.3 |
44.6 |
|
Specificity |
95.8 |
72.7 |
79.3 |
|
|
Positive LR |
8.26 |
1.44 |
2.16 |
|
|
Anti-CCP |
Sensitivity |
39.2 |
39.3 |
42.9 |
|
Specificity |
91.7 |
66.9 |
70.7 |
|
|
Positive LR |
4.70 |
1.19 |
1.46 |
|
|
|
||||
|
Combinations of antibodies (rheumatoid factor (RF) and/or anti-Sa and/or anti-cyclic citrullinated peptide (anti-CCP)) are not shown, because none brought any improvement over the detection of anti-Sa alone. LR, likelihood ratio; RA, rheumatoid arthritis. |
||||
|
Boire et al. Arthritis Research & Therapy 2005 7:R592 doi:10.1186/ar1719 |
||||
